Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von OldOrangeEyes 

Amicus Therapeutics Inc. diskutieren

Amicus Therapeutics Inc.

WKN: A0MSMZ / Symbol: FOLD / Name: Amicus / Aktie / Pharmazeutika / Mid Cap /

8,30 €
-0,60 %

Einschätzung Buy
Rendite (%) -7,22 %
Kursziel 20,29
Veränderung
Endet am 15.01.26

Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $21.00 price target on the stock.
Ratings data for FOLD provided by MarketBeat

Einschätzung Buy
Rendite (%) -4,02 %
Kursziel 16,27
Veränderung
Endet am 20.02.26

Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at Wells Fargo & Company from $18.00 to $17.00. They now have an "overweight" rating on the stock.
Ratings data for FOLD provided by MarketBeat

Einschätzung Buy
Rendite (%) 25,00 %
Kursziel 11,85
Veränderung
Endet am 18.09.26

Amicus Therapeutics (NASDAQ:FOLD) was upgraded by analysts at Needham & Company LLC from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock.
Ratings data for FOLD provided by MarketBeat

Amicus Therapeutics (NASDAQ:FOLD) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Ratings data for FOLD provided by MarketBeat

Einschätzung Buy
Rendite (%) 9,15 %
Kursziel 16,51
Veränderung
Endet am 06.11.26

Amicus Therapeutics (NASDAQ:FOLD) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $19.00. They now have an "overweight" rating on the stock.
Ratings data for FOLD provided by MarketBeat